Lineage Cell Therapeutics Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
77
- Stock Symbol
-
LCTX
- Investments
-
7
- Share Price
-
$0.47
- (As of Wednesday Closing)
Lineage Cell Therapeutics General Information
Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Contact Information
Website
www.lineagecell.comCorporate Office
- 2173 Salk Avenue
- Suite 200
- Carlsbad, CA 92008
- United States
Corporate Office
- 2173 Salk Avenue
- Suite 200
- Carlsbad, CA 92008
- United States
Lineage Cell Therapeutics Timeline
Lineage Cell Therapeutics Stock Performance
As of 23-Apr-2025, Lineage Cell Therapeutics’s stock price is $0.47. Its current market cap is $108M with 228M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.47 | $0.43 | $0.37 - $1.40 | $108M | 228M | 1.42M | -$0.09 |
Lineage Cell Therapeutics Financials Summary
As of 31-Dec-2024, Lineage Cell Therapeutics has a trailing 12-month revenue of $9.5M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 79,406 | 79,406 | 151,026 | 133,922 |
| Revenue | 9,499 | 9,499 | 8,945 | 14,703 |
| EBITDA | (19,688) | (19,688) | (24,219) | (25,914) |
| Net Income | (18,609) | (18,609) | (21,486) | (26,273) |
| Total Assets | 113,218 | 113,218 | 101,019 | 123,664 |
| Total Debt | 2,514 | 2,514 | 2,952 | 3,896 |
Lineage Cell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lineage Cell Therapeutics Comparisons
Industry
Financing
Details
Lineage Cell Therapeutics Competitors (57)
One of Lineage Cell Therapeutics’s 57 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| U.S. Stem Cell | Formerly VC-backed | Sunrise, FL | ||||
| Harmony Biosciences | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Sernova | Corporation | London, Canada | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA |
Lineage Cell Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lineage Cell Therapeutics Patents
Lineage Cell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4486358-A1 | Methods and compositions for treating hearing loss | Pending | 02-Mar-2022 | ||
| US-20250057886-A1 | Methods and compositions for treating hearing loss | Pending | 02-Mar-2022 | ||
| JP-2025507829-A | Methods and compositions for treating hearing loss | Pending | 02-Mar-2022 | ||
| AU-2023228602-A2 | Methods and compositions for treating hearing loss | Pending | 02-Mar-2022 | ||
| AU-2023228602-A1 | Methods and compositions for treating hearing loss | Pending | 02-Mar-2022 | A61K35/36 |
Lineage Cell Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lineage Cell Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lineage Cell Therapeutics Investments & Acquisitions (7)
Lineage Cell Therapeutics’s most recent deal was a Merger/Acquisition with Asterias Biotherapeutics. The deal was made on 11-Mar-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Asterias Biotherapeutics | 11-Mar-2019 | Merger/Acquisition | Drug Discovery | ||
| Cell Cure Neurosciences | 18-Jun-2017 | Secondary Transaction - Private | Biotechnology | ||
| Cell Cure Neurosciences | 16-Feb-2016 | Secondary Transaction - Private | Biotechnology | ||
| Geron Corporation (Stem Cell Assets) | 01-Oct-2013 | Merger/Acquisition | Biotechnology | ||
| Recyte Therapeutics | 24-Mar-2011 | Seed Round | Drug Discovery |
Lineage Cell Therapeutics ESG
Risk Overview
Risk Rating
Updated January, 04, 2024
26.32 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Lineage Cell Therapeutics Exits (1)
Lineage Cell Therapeutics’s most recent exit was on 24-Mar-2011 from Recyte Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Recyte Therapeutics | 24-Mar-2011 | Completed |
|
Lineage Cell Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cell Cure Neurosciences | Jerusalem, Israel | 2005 |
Lineage Cell Therapeutics FAQs
-
When was Lineage Cell Therapeutics founded?
Lineage Cell Therapeutics was founded in 1990.
-
Where is Lineage Cell Therapeutics headquartered?
Lineage Cell Therapeutics is headquartered in Carlsbad, CA.
-
What is the size of Lineage Cell Therapeutics?
Lineage Cell Therapeutics has 77 total employees.
-
What industry is Lineage Cell Therapeutics in?
Lineage Cell Therapeutics’s primary industry is Drug Discovery.
-
Is Lineage Cell Therapeutics a private or public company?
Lineage Cell Therapeutics is a Public company.
-
What is Lineage Cell Therapeutics’s stock symbol?
The ticker symbol for Lineage Cell Therapeutics is LCTX.
-
What is the current stock price of Lineage Cell Therapeutics?
As of 23-Apr-2025 the stock price of Lineage Cell Therapeutics is $0.47.
-
What is the current market cap of Lineage Cell Therapeutics?
The current market capitalization of Lineage Cell Therapeutics is $108M.
-
What is Lineage Cell Therapeutics’s current revenue?
The trailing twelve month revenue for Lineage Cell Therapeutics is $9.5M.
-
Who are Lineage Cell Therapeutics’s competitors?
Allogene Therapeutics, U.S. Stem Cell, Harmony Biosciences, Sernova, and SAGE Therapeutics are some of the 57 competitors of Lineage Cell Therapeutics.
-
What is Lineage Cell Therapeutics’s annual earnings per share (EPS)?
Lineage Cell Therapeutics’s EPS for 12 months was -$0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
